GLP-1 Medications: How Semaglutide and Tirzepatide Work

GLP-1 medications don't burn fat or rev your metabolism. They work one step upstream, on a signal your gut already sends after a meal to tell your brain you've had enough. Semaglutide and tirzepatide make that signal louder and hold it longer, which is why the background hum of hunger fades on them. Knowing the actual biology is what separates treating these drugs as a trend from using them as medicine.

If you've lost weight a dozen times and watched it climb back every time, the problem usually isn't your discipline. Your body defends a weight set point with hunger hormones, and that defense gets louder the more you diet. These medications act on that exact system. Below: how they work, where semaglutide and tirzepatide split, who they fit, and what an honest month-by-month arc looks like.

What GLP-1 actually is

GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine releases when food arrives. It's part of the conversation your gut has with your brain about whether you're satisfied. Semaglutide and tirzepatide are receptor agonists, meaning they bind the same receptors natural GLP-1 binds and switch them on. They outperform the hormone you make for one reason: your own GLP-1 breaks down within a couple of minutes, while these are engineered to last about a week, so the signal stays steady instead of flickering on and off around meals.

Three mechanisms run at once. It helps to see them as separate jobs rather than one vague effect.

1. 1.Appetite signaling in the brain. The drug acts on receptors in the hypothalamus, the region that governs hunger and fullness. For many people this shows up as less food noise, the low-grade preoccupation with the next snack that tends to spike in the evening.
2. 2.Slower gastric emptying. Your stomach passes its contents into the intestine more gradually, so a normal portion keeps you full longer and you hit satiety on less.
3. 3.Steadier blood sugar. The drug improves glucose-dependent insulin release and lowers glucagon, smoothing the post-meal swings that drive cravings. GLP-1s started as diabetes medicines for this reason, before anyone mapped the weight effects.

Semaglutide and tirzepatide are different drugs

People use the names interchangeably, partly because of the brands in circulation: semaglutide sells as Ozempic and Wegovy, tirzepatide as Mounjaro and Zepbound. The meaningful difference is how many receptors each one hits. Semaglutide is a single agonist, hitting only the GLP-1 receptor. Tirzepatide is a dual agonist, hitting GLP-1 and a second receptor called GIP. That added GIP activation appears to amplify the effect on appetite and metabolism, and it shows up on the scale.

SURMOUNT-5 compared the two head to head over 72 weeks, and tirzepatide produced greater average weight loss. That bigger number doesn't make it your right pick. Tolerance, your goals, your medical history, and how your body responds all factor in, and the dual mechanism carries trade-offs for some people. A physician matches the drug to the person with your labs in front of them, not by defaulting to the higher figure.

What the first six months realistically look like

Nobody starts at the full dose. Treatment begins low and steps up over time, and the arc follows a recognizable shape. These ranges come from trial populations, not a forecast for any one person. Your starting weight, dose, and habits all move the curve.

• First few weeks: appetite usually starts to drop as the medication takes hold. Titration also begins here, so some people feel mild nausea or fullness as the dose rises. Weight change tends to be modest; the early win is quieter food noise.
• Months one to three: as the dose climbs toward maintenance, weight loss tends to steady. Many people find they're satisfied with portions that used to leave them wanting more.
• Months three to six and on: loss generally continues toward the trial-class averages, then slows as the body settles toward a new equilibrium. This is where protein and resistance training protect muscle and hold the change in place.

The side effects, honestly

The common side effects are gastrointestinal: nausea most of all, sometimes vomiting, diarrhea, constipation, or reflux. They're dose-dependent, so they tend to appear or worsen right after a dose increase, then settle as your body adapts. In SURMOUNT-1, nausea ran from about 24% at lower tirzepatide doses to roughly 33% at the highest, against about 9% on placebo. Real, but for most people mild to moderate and easing over time rather than constant.

Many of the horror stories online trace back to dosing that moved too fast. The nausea people describe as flattening them is usually a titration problem, not a fixed property of the drug. Eating slower, stopping at comfortably full instead of stuffed, smaller portions, and staying hydrated all help. A physician adjusts the pace to how you actually respond rather than rushing you to a target dose.

Why slow titration and supervision do the real work

Titration is the gradual dose escalation, usually over about 16 to 20 weeks, that brings you up to a maintenance dose in steps. It exists to give your digestive system time to adapt so side effects stay manageable. Skip steps or escalate too fast and the risk of severe nausea and vomiting climbs, which is the most common way people quit before the medication has had a chance to work.

This is where a board-certified physician earns their place. A clinician sets the pace to your tolerance, adjusts the dose by response and bloodwork, catches contraindications before they become problems, and changes course when something isn't working. The slow, supervised version is the one most people can actually stay on, and staying on it is what makes the medication pay off.

What happens if you stop

This is the honest answer to the question most people are sitting on but rarely ask. The appetite effect depends on the medication being present. When you stop, appetite tends to return, and without a plan, some regain is common. That isn't a flaw unique to these drugs. It's how a chronic-condition treatment behaves when you remove it, the same way blood pressure drifts back up after you stop a blood-pressure medication.

So a serious program treats this as ongoing care rather than a sprint to a number. Building nutrition, adequate protein, and resistance training during your time on the medication, plus a deliberate maintenance strategy, is what makes results last. The medication makes the change feel possible. The habits and the maintenance plan carry it forward.

Pharmacy-grade and supervised, not a vial off the internet

There's a wide gap between a prescription program and a gray-market seller pushing research peptides in unlabeled vials. The unsupervised route skips the steps that keep treatment effective and safe: the evaluation, the contraindication screening, the bloodwork, the dose adjustments, the part where someone watches your response. Those steps aren't paperwork. They separate a smooth experience from a miserable one, and occasionally a safe one from a dangerous one.

Oriah's model is the supervised version of what this article describes. A board-certified physician reviews your health history and bloodwork, prescribes pharmaceutical-grade semaglutide or tirzepatide from licensed US pharmacies, and titrates the dose to your tolerance and labs over time. It's available in all 50 states, from $99 a month, no insurance needed, no waiting room. If a clinician decides it isn't right for you, you won't be prescribed it, which is the point of evaluating first.